Reaction Details |
| Report a problem with these data |
Target | Cyclin-dependent kinase 9 |
---|
Ligand | BDBM50528817 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_2270751 |
---|
IC50 | <4.0±n/a nM |
---|
Citation | Marak, BN; Dowarah, J; Khiangte, L; Singh, VP A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents. Eur J Med Chem203:0 (2020) [PubMed] |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Cyclin-dependent kinase 9 |
---|
Name: | Cyclin-dependent kinase 9 |
Synonyms: | C-2K | CDC2L4 | CDK9 | CDK9_HUMAN | Cell division cycle 2-like protein kinase 4 | Cell division protein kinase 9 | Cyclin-Dependent Kinase 9 (CDK9) | Cyclin-dependent kinase 9 (CDK9) | Serine/threonine-protein kinase PITALRE | TAK | Tat-associated kinase complex catalytic subunit |
Type: | Enzyme Subunit |
Mol. Mass.: | 42789.13 |
Organism: | Homo sapiens (Human) |
Description: | n/a |
Residue: | 372 |
Sequence: | MAKQYDSVECPFCDEVSKYEKLAKIGQGTFGEVFKARHRKTGQKVALKKVLMENEKEGFP
ITALREIKILQLLKHENVVNLIEICRTKASPYNRCKGSIYLVFDFCEHDLAGLLSNVLVK
FTLSEIKRVMQMLLNGLYYIHRNKILHRDMKAANVLITRDGVLKLADFGLARAFSLAKNS
QPNRYTNRVVTLWYRPPELLLGERDYGPPIDLWGAGCIMAEMWTRSPIMQGNTEQHQLAL
ISQLCGSITPEVWPNVDNYELYEKLELVKGQKRKVKDRLKAYVRDPYALDLIDKLLVLDP
AQRIDSDDALNHDFFWSDPMPSDLKGMLSTHLTSMFEYLAPPRRKGSQITQQSTNQSRNP
ATTNQTEFERVF
|
|
|
BDBM50528817 |
---|
n/a |
---|
Name | BDBM50528817 |
Synonyms: | CHEMBL4462530 | US10717746, Example 14 | US20230416221, Compound AZD4573 |
Type | Small organic molecule |
Emp. Form. | C22H28ClN5O2 |
Mol. Mass. | 429.943 |
SMILES | CC(=O)N[C@@H]1CCC[C@@H](C1)C(=O)Nc1cc(-c2cnn3CC(C)(C)Cc23)c(Cl)cn1 |r| |
Structure |
|